United States Cell Therapy Manufacturing Market By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies), By Source of Cell (Autologous v/s Allogenic), By Scale of Operation (Preclinical, Clinical, Commercial), By Source (In-House v/s Contract Manufacturing), By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others), By End User (Phar
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationUnited States Cell Therapy Manufacturing Market By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies), By Source of Cell (Autologous v/s Allogenic), By Scale of Operation (Preclinical, Clinical, Commercial), By Source (In-House v/s Contract Manufacturing), By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others), By End User (Phar
The United States Cell Therapy Manufacturing Market is expected to grow at an impressive rate during the forecast period, 2024-2028, owing to favorable regulatory policies, increasing investment, technological advancements, a collaborative ecosystem, and a rising prevalence of chronic diseases. A pioneering field in medicine, known as cell therapy, has evolved, promising treatments for diseases that were once considered inoperable. With tremendous expansion in recent years, the United States has established itself as a leader in cell therapy manufacturing.
The existence of a favorable regulatory framework is one of the primary drivers of the cell therapy manufacturing sector in the United States. Regulatory agencies like the U.S. Food and Drug Administration (FDA) have implemented procedures to speed up the creation and marketing of cell therapies. By reducing entrance barriers and encouraging innovation, programs like the Regenerative Medicine Advanced Therapy (RMAT) designation and expedited clearance procedures have simplified the manufacturing processes for cell therapy manufacturers.
The expansion of the cell therapy manufacturing sector in the United States has been significantly fueled by advancements in technology and manufacturing infrastructure. Manufacturing procedures for cell treatment have become more effective, scalable, and reproducible due to automation and closed-system processing. Cutting-edge technologies including bioreactors, 3D bioprinting, and gene editing tools have enhanced the effectiveness and caliber of cell therapies. These innovations have increased patient access to cell therapies while also improving production capacity and lowering prices.
Effective cell therapies are in great demand due to the rising incidence of chronic and degenerative diseases such as cancer, cardiovascular problems, and neurological issues. With an aging population and a high disease prevalence, the United States offers an enormous market for the production of cell therapies. A large-scale manufacturing infrastructure is required to keep up with the rising demand for cell therapies as clinical trials for a variety of illnesses have shown encouraging outcomes.
Cell therapies are essential to the paradigm shift in personalized and precision medicine, which is gaining pace. Cell treatments can be tailored to each patient, enhancing therapy efficacy and reducing side effects as the knowledge of molecular biology and genetics advances. The demand for specialized cell therapy manufacturing techniques that can accommodate patient-specific therapies, such as autologous therapies that employ a patient's own cells for treatment, is anticipated to increase as a result of this trend.
Although autologous cell therapies have demonstrated encouraging outcomes, scaling and manufacturing complexity remain challenges. The development of over-the-counter allogeneic treatments is progressing to overcome these limitations. Allogeneic therapies involve healthy donor cells that can be amplified and produced in large quantities. The availability of well-characterized donor cell lines and advancements in gene editing technologies like CRISPR-Cas9 are expected to drive the increase in allogeneic cell therapy manufacturing in the United States.
The landscape of cell therapy manufacturing is about to undergo a shift due to the integration of advanced production technology. To improve productivity, reproducibility, and quality control, manufacturing processes are being automated, robotized, and enhanced with AI. With the use of these technologies, cell therapy production can be evaluated in real-time, throughput can be improved, and scaling up can be done quickly. Closed-system manufacturing platforms are also used, which reduces the chance of contamination and increase the overall safety level for cell treatments.
An intricate and interrelated supply chain, including raw materials, reagents, and accessory parts, is used in the manufacturing of cell therapy products. A significant focus on supply chain optimization is necessary to guarantee the seamless manufacture and delivery of cell treatments. To meet the growing demand for cell treatments and ensure their prompt delivery to patients, it is essential to streamline logistics, secure the availability of high-quality starting materials, and implement strong quality management systems.
The United States cell therapy manufacturing market is a rapidly growing market that provides encouraging treatments for diseases that were once incurable. Although the sector has a lot of potential to grow, there are also challenges in its way. The inherent complexity of the manufacturing process is one of the main challenges associated with cell therapy. Cell therapies, compared to conventional pharmaceutical production, involve working with live, sensitive cells that require specific environments to thrive and expand. Keeping cells healthy, consistent, and viable throughout the production process is a difficult task. The production process is more complex as it requires aseptic processing, strict quality control, and regulatory compliance. To ensure scalable, reproducible, and cost-effective manufacturing processes, it is necessary to invest in cutting-edge technology, automation, and process optimization.
The production of cell therapies requires a complex supply network that includes raw materials, chemicals, growth factors, and supporting elements. To prevent disruptions and preserve the integrity of the product, a reliable and robust supply chain is necessary. The manufacturing process and the outcome of the product can be influenced by the availability, quality, and consistency of raw materials. To establish standards, improve logistics, and ensure the availability of high-quality materials for cell therapy manufacturing, collaboration between manufacturers, suppliers, and regulatory bodies is crucial.
Growing Prevalence of Chronic Diseases
The growth of the cell therapy manufacturing market in the United States is expected to be significantly impacted by the rising prevalence of chronic diseases. Chronic diseases create a significant burden on individuals, healthcare systems, and the economy. Examples include cancer, cardiovascular disease, diabetes, and neurodegenerative disorders. There is an enormous unmet need for novel drugs because conventional therapies for these disorders frequently have inadequate efficacy or simply address symptoms. Cell treatment can help in this situation. With the possibility of disease modification, tissue regeneration, and individualized treatment methods, cell treatments have demonstrated significant promise in clinical trials for a variety of chronic diseases. Cell therapy production will be crucial in providing these needs as they continue to grow, given the demand for efficient and long-lasting treatments.
Production of cellular products, comprising genetically modified cells, stem cells, and immune cells that can be used by patients to treat the underlying causes of chronic diseases, is made possible by cell therapy manufacturing. To ensure widespread patient access and commercial sustainability, it is essential that these medicines can be produced on a large scale and with consistent quality. The rising incidence of chronic diseases will result in a greater demand for cell therapies, necessitating the expansion of production capacity.
Technological Advancements
Advances in technology in cell therapy are anticipated to have a big impact on the expansion of the cell therapy manufacturing industry in the United States. Cell therapies can now be developed and produced in novel ways owing to the quick development of technologies like gene editing, automation, and bioprocessing. These innovations provide several significant advantages that will fuel the expansion of the manufacturing market.
Gene editing has been transformed by technologies like CRISPR-Cas9, which permit precise alterations to cellular DNA and increase the therapeutic potential of cell treatments. This level of accuracy enables the creation of highly customized and targeted medicines, improving patient outcomes. The efficiency, reproducibility, and scalability of manufacturing processes have all increased because of automation and robotics.
Automation reduces the risk of human error and improves the entire production workflow by handling complex operations, including cell culture expansion, media exchange, and quality control. Additionally, developments in bioprocessing, such as the creation of bioreactors and 3D bioprinting, have made it easier to produce intricate and useful cellular structures. These developments increase the therapeutic potential of cell treatments by enabling the development of tissue-like structures and the controlled differentiation of stem cells. Additionally, technological developments have assisted in creating closed-system processing, which guarantees aseptic conditions and reduces the possibility of contamination, essential for maintaining the safety and quality of cell treatments.
By enhancing product quality, boosting production capacity, and lowering costs, these technologies are expected to accelerate the development of the cell therapy manufacturing market in the United States as they continue to advance and become more widely found at.
Market Segmentation
The United States Cell Therapy Manufacturing Market can be segmented by therapy, source of cell, scale of operation, source, application, end user, region and competitive landscape. By therapy, the United States Cell Therapy Manufacturing Market can be segmented into T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, and Stem Cell Therapies. Based on the source of cell, the market is divided into Autologous and Allogenic. Based on the scale of operation, the market is divided into Preclinical, Clinical, and Commercial. Based on the source, the United States Cell Therapy Manufacturing Market is divided into In-House and Contract Manufacturing. Based on the application, the Market is divided into Oncology, Cardiovascular Diseases, Orthopedic Diseases, and Others. Based on the end user, the market is divided into pharmaceutical & biotechnology companies, academic & research institutes, and Others.
Market Players
Lonza Group AG, Thermo Fisher Scientific Inc., GE Healthcare Life Sciences, Merck KGaA, Fujifilm Holdings Corporation, Novartis International AG, Bristol Myers Squibb (BMS), Precision Biosciences Inc. are among others some of the leading companies operating in the market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | By Therapy By Source of Cell By Scale of Operation By Source By Application By End User |
| Regional scope | Northeast Region; Midwest Region; South Region; West Region |
| Key companies profiled | Lonza Group AG, Thermo Fisher Scientific Inc., GE Healthcare Life Sciences, Merck KGaA, Fujifilm Holdings Corporation, Novartis International AG, Bristol Myers Squibb (BMS), Precision Biosciences Inc. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Report Scope
In this report, United States Cell Therapy Manufacturing Market has been segmented into following categories, in addition to the industry trends which have also been detailed below
- United States Cell Therapy Manufacturing Market, By Therapy
- T-Cell Therapies
- Dendritic Cell Therapies
- Tumor Cell Therapies
- Stem Cell Therapies
- United States Cell Therapy Manufacturing Market, By Source of Cell
- Autologous
- Allogenic
- United States Cell Therapy Manufacturing Market, By Scale of Operation
- Preclinical
- Clinical
- Commercial
- United States Cell Therapy Manufacturing Market, By Source
- In-House
- Contract Manufacturing
- United States Cell Therapy Manufacturing Market, By Application
- Oncology
- Cardiovascular Diseases
- Orthopedic Diseases
- Others
- United States Cell Therapy Manufacturing Market, By End User
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Others
Competitive Landscape
Company Profiles
found at Customizations
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are found at for the report
Company Information
- Detailed analysis and profiling of additional market players (up to five).
It is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy